drugset
drugset / Trial / NCT06255028

A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases

NCT06255028 ↗

Phase 1 Active not recruiting 6 enrolled Century Therapeutics, Inc.
Non-randomizedSequentialOpen-labelTreatment

Summary

CALiPSO-1 is a Phase 1, multi-centre, dose-confirmation study to evaluate the safety and efficacy of CNTY-101 in participants with refractory B cell-mediated autoimmune diseases including those with moderate to severe systemic lupus erythematosus (SLE) with or without lupus nephritis (LN), idiopathic inflammatory myopathies (IIM), and diffuse cutaneous systemic sclerosis (DcSSc).

Timeline

Start
2025-02-06
Primary completion
2028-08
Completion
2028-08

Drugs

EvaluationDrugModalityDoseRoute
Subject CNTY-101 Cell therapy — Intravenous
Background IL-2 Protein / enzyme biologic — Subcutaneous

Indications

diffuse cutaneous systemic sclerosis idiopathic inflammatory myopathy lupus nephritis systemic lupus erythematosus